Table 3 Univariate analysis showing correlation between baseline factors and completion of ipilimumab induction therapy (3 mg/kg every 3 weeks for a total of four doses)
Characteristic | Slow progressors n (%) | Rapid progressors n (%) | P value |
|---|---|---|---|
Gender | |||
Male | 10 (56) | 8 (44) | 0.82 |
Female | 6 (60) | 4 (40) | |
Age | |||
<50 years | 5 (36) | 9 (64) | 0.02 |
≥50 years | 11(79) | 3 (21) | |
ECOG PS | |||
0 | 12 (80) | 3 (20) | 0.009 |
1 | 4 (31) | 9 (69) | |
Previous lines of therapy | |||
0 | 9 (64) | 5 (36) | 0.44 |
1 | 7 (50) | 7 (50) | |
Brain metastasis | |||
Yes | 0 (0) | 7 (100) | <0.0001 |
No | 16 (76) | 5 (24) | |
LDH | |||
<1.10 ULN | 13 (93) | 1 (7) | <0.001 |
≥1.10 ULN | 3 (21) | 11 (79) | |
BRAF inhibitor | |||
Vemurafenib | 7 (58) | 5 (42) | 0.91 |
Dabrafenib | 9 (56) | 7 (44) | |